Now that the election is over, many fund managers are deciding whether to re-position in stocks that are supposed to be winners in soon-to-be President Barrack Obama’s gameplan. Let’s start with a names that may be a winner: Teva Pharmaceuticals (TEVA) is a generic drug-maker that stands to benefit from the administrations desire to bring drug [...]